<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925935</url>
  </required_header>
  <id_info>
    <org_study_id>AB-205-001</org_study_id>
    <nct_id>NCT03925935</nct_id>
  </id_info>
  <brief_title>Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation</brief_title>
  <official_title>A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiocrine Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Angiocrine Bioscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin&#xD;
      lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without&#xD;
      radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205&#xD;
      infusion following autologous stem cell transfusion on Day 0.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>AB-205 dose escalation based on safety.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea.</measure>
    <time_frame>Day 0 to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>First of three consecutive days after ASCT of absolute neutrophil count (ANC) &gt; 500/μL</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>First of seven consecutive days after ASCT of platelet count ≥ 20,000/μL without transfusion support</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid recovery</measure>
    <time_frame>14, 28 and 100 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 sequential dose escalation cohorts of AB-205</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AB-205</intervention_name>
    <description>Engineered human umbilical vein endothelial cells</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) who are candidates&#xD;
             for HDT-ASCT with one of the following conditioning regimens:&#xD;
&#xD;
               -  carmustine, etoposide, cytarabine, melphalan (BEAM)&#xD;
&#xD;
               -  cyclophosphamide, carmustine, etoposide (CBV)&#xD;
&#xD;
               -  thiotepa, busulphan, cyclophosphamide (TBC)&#xD;
&#xD;
               -  additional myeloablative chemotherapy-based conditioning regimens may be&#xD;
                  permitted with the approval of the medical monitor&#xD;
&#xD;
          -  Adjunct radiation therapy to HDT will be allowed.&#xD;
&#xD;
          -  Adequate organ function is required, defined as follows:&#xD;
&#xD;
               -  Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia&#xD;
&#xD;
               -  AST, ALT, and alkaline phosphatase &lt; 3 times the upper limit of normal&#xD;
&#xD;
               -  Creatinine clearance ≥ 40 ml/min (calculated by Cockcroft Gault)&#xD;
&#xD;
               -  LVEF ≥ 45% by MUGA or resting echocardiogram&#xD;
&#xD;
               -  Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted&#xD;
&#xD;
               -  Adequate performance status ECOG ≤1&#xD;
&#xD;
          -  For female subjects of childbearing potential:&#xD;
&#xD;
               -  A negative serum or urine pregnancy test at screening.&#xD;
&#xD;
               -  Subject must be willing to use a recommended method of contraception from the&#xD;
                  start of the screening period and throughout the study period.&#xD;
&#xD;
          -  For males who can father a child and are having intercourse with females of&#xD;
             childbearing potential who are not using adequate contraception:&#xD;
&#xD;
             - Subject must be willing to use a recommended method of contraception and refrain&#xD;
             from sperm donation from the start of conditioning therapy for at least 1 year after&#xD;
             completion and discussion with a treating physician.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, drug administration plan,&#xD;
             protocol-specified laboratory tests, other study procedures, and study restrictions.&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  History of prior ASCT.&#xD;
&#xD;
          -  Active malignancy other than the one for which the subject is undergoing HDT-ASCT.&#xD;
             (Subjects with cervical carcinoma in situ or localized basal or squamous cell&#xD;
             carcinoma treated with definitive surgery are eligible.)&#xD;
&#xD;
          -  Subjects with a serious concomitant medical condition that could interfere with the&#xD;
             conduct of the clinical trial, such as unstable angina, renal failure requiring&#xD;
             hemodialysis, or active infection requiring IV antibiotics.&#xD;
&#xD;
          -  Active Human Immunodeficiency Virus (HIV) infection and Acquired Immunodeficiency&#xD;
             Syndrome (AIDS).&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed&#xD;
             during treatment and for an additional 30 days or longer after chemotherapy treatment&#xD;
             discontinuation if required by prescribing information for chemotherapy agents&#xD;
             received during the study.&#xD;
&#xD;
          -  Subjects who have known hypersensitivity reactions to bovine (cow) proteins or&#xD;
             documented allergy to DMSO.&#xD;
&#xD;
          -  Subject has other conditions that in the opinion of the investigator would place the&#xD;
             subject at increased risk for toxicity by participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Kavalerchik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiocrine Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

